Bristol-Myers Squibb 1Q

1Q Revenues: $5.0 billion (+3%)

1Q Earnings: $638 million (-3.5%)

Comments: Biopharmaceutical sales totaled $4.3 billion in the quarter, with U.S. sales up 13% to $2.8 billion and International sales down 11% to $1.5 billion (+2% excluding foreign exchange impact). Sales growth in the quarter was led by key drivers including Abilify, up 30% to $589 million, and Plavix, up 10% to $1.4 billion. Sales of Orencia grew 43% to $124 million and Sprycel sales were up 33% to $88 million. Reyataz sales were $322 million (+8%). Baraclude sales were $152 million (+41%). Erbitux sales were down 12% to $164 million.